Biopharmaceutical company registered in Ireland with its United States operations at Waltham in Massachusetts and manufacturing at Wilmington in Ohio and Athlone in Ireland, formed in 2011 when Alkermes of Massachusetts combined with Elan Drug Technologies and listed on Nasdaq. Develops and sells medicines for central nervous system disorders including aripiprazole lauroxil, naltrexone and buprenorphine products for addiction and olanzapine and samidorphan for schizophrenia and bipolar disorder, and uses its own long acting injectable and oral drug delivery technologies, licensing them to other companies.
Aucun commentaire disponible.
Laissez votre note & commentaire